Premium
Thiazolidinediones May Not Reduce Diabetes Incidence in Type 1 Diabetes
Author(s) -
SHIGIHARA TOSHIKATSU,
OKUBO YOSHIAKI,
KANAZAWA YASUHIKO,
OIKAWA YOICHI,
SHIMADA AKIRA
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1375.056
Subject(s) - pioglitazone , metformin , medicine , insulitis , diabetes mellitus , rosiglitazone , troglitazone , endocrinology , nod mice , glycemic , type 2 diabetes , insulin resistance , nod , peroxisome proliferator activated receptor , receptor
Abstract: Thiazolidinediones improve glycemic control by reducing insulin resistance. Some studies have demonstrated that troglitazone had a preventative effect on diabetes in NOD (non‐obese diabetic) mice. One of the mechanisms proposed for the prevention of diabetes by thiazolidinediones is an effect on T‐helper 1/T‐helper 2 (Th1/Th2) balance. In this article, we attempted to clarify whether pioglitazone is also effective in preventing diabetes as compared to metformin, which has no immunological effect. Female NOD mice were administered pioglitazone or metformin orally, and the insulitis score, cytokines secreted from splenocytes, cytokine expression levels in the pancreas, and the incidence of diabetes after acceleration by cyclophosphamide were analyzed. We could not find any advantage of pioglitazone in preventing Th1 skewing and the development of diabetes over metformin. Therefore, further research should take place before the application of thiazolidinediones to human slowly progressive insulin‐dependent diabetes mellitus (SPIDDM) patients.